{"id":361079,"date":"2024-04-11T00:00:00","date_gmt":"2024-04-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0086-biopharma-systemic-lupus-erythematosus-epidemiology-americas\/"},"modified":"2026-03-31T10:30:26","modified_gmt":"2026-03-31T10:30:26","slug":"epidim0086-biopharma-systemic-lupus-erythematosus-epidemiology-americas","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0086-biopharma-systemic-lupus-erythematosus-epidemiology-americas\/","title":{"rendered":"Systemic Lupus Erythematosus &#8211; Epidemiology &#8211; Americas"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>, how many in each country in the developed world have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>, how many in each developed country across the world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> by clinical definition.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> by clinical definition.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with lupus nephritis.<\/li>\n<li>Diagnosed drug-treated prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with lupus nephritis.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with no flares or persistently active disease.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with flares only.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with persistently active disease only.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"systemic lupus erythematosus\">SLE<\/abbr> with flares and persistently active disease.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-361079","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-systemic-lupus-erythematosus","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/361079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/361079\/revisions"}],"predecessor-version":[{"id":361379,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/361079\/revisions\/361379"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=361079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}